CAFC to rehear NF-kappa B case en banc

The U.S. Court of Appeals for the Federal Circuit agreed to rehear en banc a suit brought by Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) against Eli Lilly and Co. (NYSE:LLY). By reinstating the appeal, the CAFC vacated its April 3 ruling that Lilly's osteoporosis drug Evista raloxifene and sepsis drug Xigris drotrecogin alfa did not infringe an Ariad patent covering methods for reducing NF-kappa B signaling activity (See BioCentury Extra, Friday, April 03, 2009). ...